{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:31:32.858894",
  "document": "03_Protocol_ALXN1720-oMG-303.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/03_Protocol_ALXN1720-oMG-303.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 13,
  "total_validated": 13,
  "total_rejected": 0,
  "genes": [
    {
      "matched_text": "C5",
      "hgnc_symbol": "C5",
      "full_name": "complement C5",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "1331",
        "entrez": "727",
        "ensembl": "ENSG00000106804",
        "uniprot": "P01031",
        "omim": "120900"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "1331",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "727",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000106804",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "120900",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P01031",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "169150",
          "disease_name": "Immunodeficiency due to a late component of complement deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "though, anti-AChR autoantibodies cause NMJ degeneration through activation of the complement system.\n\nAnti-AChR autoantibodies are immunoglobulins of the G1 and G3 subtypes which attract complement component Clq. Deposition of Clq triggers the classical complement pathway leading to the cleavage of C5 into C5a and C5b. C5b initiates the assembly of the MACs and destruction of the motor end plate (Dalakas, 2020; Gavriilaki, 2020), reducing the efficiency and reliability of neuromuscular signalling.\n\nEvidence of complement activity in anti-AChR antibody-positive gMG is provided by histopathologica",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "ADA",
      "hgnc_symbol": "ADA",
      "full_name": "adenosine deaminase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "186",
        "entrez": "100",
        "ensembl": "ENSG00000196839",
        "uniprot": "P00813",
        "omim": "608958"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "186",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "100",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000196839",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "608958",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P00813",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "277",
          "disease_name": "Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "39041",
          "disease_name": "Omenn syndrome",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "characterize the PK/PD of gefurulimab in participants with OMG e Serum gefurulimab concentrations e Absolute values, change from Baseline, and percent change from Baseline in serum free and total C5 concentrations Immunogenicity: To assess the immunogenicity to gefurulimab in participants with oMG ADA incidence, response categories, and titer over time for the duration of the study Safety: To assess the safety and tolerability of gefurulimab compared to placebo and the long-term safety and tolerability of gefurulimab in participants with OMG e Incidence and severity of AEs and SAEs e Clinically",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "MuSK",
      "hgnc_symbol": "MUSK",
      "full_name": "muscle associated receptor tyrosine kinase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "7525",
        "entrez": "4593",
        "ensembl": "ENSG00000030304",
        "uniprot": "O15146",
        "omim": "601296"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "7525",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "4593",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000030304",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "601296",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "O15146",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "994",
          "disease_name": "Fetal akinesia deformation sequence",
          "association_type": "Disease-causing germline mutation(s) (loss of function) in"
        },
        {
          "orphacode": "98913",
          "disease_name": "Postsynaptic congenital myasthenic syndrome",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "r any other intervention, at any time during this study. Alexion must be consulted if concurrent participation in a non-interventional study is considered. At the discretion of Alexion, concurrent participation in non-interventional studies may be allowed.\n\nDiagnostic Assessments\n\ne Historical anti MuSK or anti LRP-4 Ab + status\n\ne Laboratory abnormalities at the Screening Visit, including:\n\n— ALT>2 x the ULN\n\n— Direct bilirubin > 2 x ULN\n\n— Estimated glomerular filtration rate < 30 mL/min/1.73 m’ or participant on dialysis\n\n— Any other clinically significant laboratory abnormality that, in the op",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "kit",
      "hgnc_symbol": "KIT",
      "full_name": "KIT proto-oncogene, receptor tyrosine kinase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "6342",
        "entrez": "3815",
        "ensembl": "ENSG00000157404",
        "uniprot": "P10721",
        "omim": "164920"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "6342",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "3815",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000157404",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "164920",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P10721",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "158769",
          "disease_name": "Plaque-form urticaria pigmentosa",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "158766",
          "disease_name": "Typical urticaria pigmentosa",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "158778",
          "disease_name": "Isolated bone marrow mastocytosis",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "158775",
          "disease_name": "Smoldering systemic mastocytosis",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "158772",
          "disease_name": "Nodular urticaria pigmentosa",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "2884",
          "disease_name": "Piebaldism",
          "association_type": "Disease-causing germline mutation(s) (loss of function) in"
        },
        {
          "orphacode": "842",
          "disease_name": "Testicular seminomatous germ cell tumor",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "280785",
          "disease_name": "Bullous diffuse cutaneous mastocytosis",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "280794",
          "disease_name": "Pseudoxanthomatous diffuse cutaneous mastocytosis",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "566393",
          "disease_name": "Acute mast cell leukemia",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "566396",
          "disease_name": "Chronic mast cell leukemia",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "44890",
          "disease_name": "Gastrointestinal stromal tumor",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "90389",
          "disease_name": "Telangiectasia macularis eruptiva perstans",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "79455",
          "disease_name": "Cutaneous mastocytoma",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "98834",
          "disease_name": "Acute myeloblastic leukemia with maturation",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "98829",
          "disease_name": "Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)",
          "association_type": "Biomarker tested in"
        },
        {
          "orphacode": "98849",
          "disease_name": "Systemic mastocytosis with associated hematologic neoplasm",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "102724",
          "disease_name": "Acute myeloid leukemia with t(8;21)(q22;q22) translocation",
          "association_type": "Biomarker tested in"
        }
      ],
      "context": "e Section 4.3 Section 4.3 Route of SC injection SC injection Administration Use Experimental Placebo IMP or AxMP IMP IMP Sourcing Provided centrally by Alexion Provided centrally by Alexion Packaging and Gefurulimab will be provided ina _ | Placebo will be provided in a PFS-SD. Labeling PFS-SD. One kit contains 1 PFS- | One kit contains 1 PFS-SD. Kits will be SD. Kits will be labeled as labeled as required per country required per country regulations. regulations.\n\n6.2. Assignment to Study Intervention\n\nParticipants will be randomized on Day | after the Investigator has verified the eligibility c",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "FAS",
      "hgnc_symbol": "FAS",
      "full_name": "Fas cell surface death receptor",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "11920",
        "entrez": "355",
        "ensembl": "ENSG00000026103",
        "uniprot": "P25445",
        "omim": "134637"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "11920",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "355",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000026103",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "134637",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P25445",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "117",
          "disease_name": "Behçet disease",
          "association_type": "Major susceptibility factor in"
        },
        {
          "orphacode": "3261",
          "disease_name": "Autoimmune lymphoproliferative syndrome",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "3437",
          "disease_name": "Vogt-Koyanagi-Harada disease",
          "association_type": "Major susceptibility factor in"
        }
      ],
      "context": "te of 2.5%) unless stated otherwise. The summary statistics for continuous variables will include, but not be limited to, the number of patients, mean, standard deviation, minimum, median, and maximum. For categorical variables, frequencies and percentages will be presented.\n\nThe Full Analysis Set (FAS) will be the primary population used for the analysis of all efficacy endpoints for the RCT Period. Supplemental per protocol analyses for primary and secondary efficacy endpoints will be performed based on the Per Protocol Set (PPS) in the same manner as done for the FAS. Safety analyses will be p",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "C3",
      "hgnc_symbol": "C3",
      "full_name": "complement C3",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "1318",
        "entrez": "718",
        "ensembl": "ENSG00000125730",
        "uniprot": "P01024",
        "omim": "120700"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "1318",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "718",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000125730",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "120700",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P01024",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "280133",
          "disease_name": "Complement component 3 deficiency",
          "association_type": "Disease-causing germline mutation(s) (loss of function) in"
        },
        {
          "orphacode": "544472",
          "disease_name": "Atypical hemolytic uremic syndrome with complement gene abnormality",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "phase 3 pivotal ADAPT study. European Journal of Neurology. 2024;31(1):e16098.\n\nDalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16(11):601-617.\n\nEngel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267-280.\n\nGarcia Estévez DA, Lopez Diaz LM, Pardo Parrado M, et al. Epidemiology of myasthenia gravis in the province of Ourense (Galicia,",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Proc",
      "hgnc_symbol": "PROC",
      "full_name": "protein C, inactivator of coagulation factors Va and VIIIa",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "9451",
        "entrez": "5624",
        "ensembl": "ENSG00000115718",
        "uniprot": "P04070",
        "omim": "612283"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "9451",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "5624",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000115718",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "612283",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P04070",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "745",
          "disease_name": "Severe hereditary thrombophilia due to congenital protein C deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "isorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16(11):601-617.\n\nEngel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267-280.\n\nGarcia Estévez DA, Lopez Diaz LM, Pardo Parrado M, et al. Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain). Neurologia (Engl Ed). 2020;S0213-4853(20):30215-30212.\n\nGavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "itch",
      "hgnc_symbol": "ITCH",
      "full_name": "itchy E3 ubiquitin protein ligase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "13890",
        "entrez": "83737",
        "ensembl": "ENSG00000078747",
        "uniprot": "Q96J02",
        "omim": "606409"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "13890",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "83737",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000078747",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "606409",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q96J02",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "228426",
          "disease_name": "Syndromic multisystem autoimmune disease due to Itch deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "Protein therapies administered SC may | Monitoring of reactions will be done as part of routine safety cause local (injection site) and assessments, as it was done for the PREVAIL, and details will be systemic reactions. Injection site included in the CSP. reactions may include erythema, pruritus (itch), pain, and bruising. Discussion 05092025: This risk was not significant in the Prevail Systemic reactions may be immune-study and considered it low. The team agreed to retain the mitigation mediated or nonimmune and usually as proposed, with no changes needed at this stage. occur within hours of t",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Bril",
      "hgnc_symbol": "IFITM5",
      "full_name": "interferon induced transmembrane protein 5",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "16644",
        "entrez": "387733",
        "ensembl": "ENSG00000206013",
        "uniprot": "A6NNB3",
        "omim": "614757"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "16644",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "387733",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000206013",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "614757",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "A6NNB3",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "tic firing in twitch fibers of EOMs compared to limb muscles, making them more susceptible to fatigue; fewer AChRs on tonic muscles necessary for sustained gaze, making them more susceptible to receptor loss or damage and reduced expression of complement regulatory proteins on ocular muscle fibers (Bril, 2024; Soltys, 2008). A proportion of oMG patients do not achieve adequate control with current SoC treatment (Behbehani, 2023; Kerty, 2014), resulting in chronic and fluctuating diplopia and ptosis. Effective management of oMG requires continuous control of the mechanisms responsible for the disea",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Task",
      "hgnc_symbol": "KCNK3",
      "full_name": "potassium two pore domain channel subfamily K member 3",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "6278",
        "entrez": "3777",
        "ensembl": "ENSG00000171303",
        "uniprot": "O14649",
        "omim": "603220"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "6278",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "3777",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000171303",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "603220",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "O14649",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "ns, which is critical in a chronic disease such as oMG. The length of OLE Period will further support the sustained improvement in ocular signs and symptoms.\n\nEligibility criteria and outcome measures have been chosen based on a review of comparable clinical studies, recommendations provided by the Task Force on MG Study Design of the Medical Scientific Advisory Board of the MGFA (Benatar, 2012), and advice from experts in the field of oMG research.\n\nThe study will include adults with oMG corresponding to MGFA Classification Class I to evaluate the therapeutic potential of gefurulimab in participa",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "LRP-4",
      "hgnc_symbol": "LRP4",
      "full_name": "LDL receptor related protein 4",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "6696",
        "entrez": "4038",
        "ensembl": "ENSG00000134569",
        "uniprot": "O75096",
        "omim": "604270"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "6696",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "4038",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000134569",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "604270",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "O75096",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "ntervention, at any time during this study. Alexion must be consulted if concurrent participation in a non-interventional study is considered. At the discretion of Alexion, concurrent participation in non-interventional studies may be allowed.\n\nDiagnostic Assessments\n\ne Historical anti MuSK or anti LRP-4 Ab + status\n\ne Laboratory abnormalities at the Screening Visit, including:\n\n— ALT>2 x the ULN\n\n— Direct bilirubin > 2 x ULN\n\n— Estimated glomerular filtration rate < 30 mL/min/1.73 m’ or participant on dialysis\n\n— Any other clinically significant laboratory abnormality that, in the opinion of the I",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "tape",
      "hgnc_symbol": "CC2D1A",
      "full_name": "coiled-coil and C2 domain containing 1A",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "30237",
        "entrez": "54862",
        "ensembl": "ENSG00000132024",
        "uniprot": "Q6P1N0",
        "omim": "610055"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "30237",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "54862",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000132024",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "610055",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q6P1N0",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "acebo using a centralized RTSM.\n\nDRAFT 18 Sep 2025\n\nProtocol Concept Sheet ALXN1720-oMG-303/D6783C00001\n\n6.3. Masking\n\nPFS-SDs containing gefurulimab or placebo will be provided in identical study intervention kits and with identical labels for all participants in the RCT Period. Yellow transparent tape will cover the PFS-SDs to conceal the color difference between gefurulimab and placebo. Because the viscosity of gefurulimab also differs from the placebo formulation, a moderately different injection force will be required for its administration. To maintain the mask despite this difference in vis",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "PROs",
      "hgnc_symbol": "PROS1",
      "full_name": "protein S",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "9456",
        "entrez": "5627",
        "ensembl": "ENSG00000184500",
        "uniprot": "P07225",
        "omim": "176880"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "9456",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "5627",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000184500",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "176880",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P07225",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "92025: Diplopia or Ptosis will not compromise consent comprehension or PRO completion because we are able to consent people who are severely visually compromised. Consents are just read out to them by someone else and then we ask for comprehension. Consent would be read out to people who need help. PROs could be completed by asking them over the phone for remote visits. If they have ptosis, it's painful when you are lifting one eyelid. In case anybody has severe ptosis, we can always ask the questions and then the administrator can note down the responses. Risk 3: Diagnostic Misclassification: Ris",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    }
  ]
}